Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
6978 Stock Chart & Stats
HK$2.68
-HK$0.01(-0.43%)
At close: 4:00 PM EST
HK$2.68
-HK$0.01(-0.43%)
Day’s Range― - ―
52-Week RangeHK$2.38 - HK$5.65
Previous CloseN/A
Volume50.00K
Average Volume (3M)1.34M
Market Cap
HK$1.57B
Enterprise ValueHK$1.26B
Total Cash (Recent Filing)HK$21.05M
Total Debt (Recent Filing)HK$111.73M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Mar 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding617,500,800
10 Day Avg. Volume1,608,107
30 Day Avg. Volume1,338,788
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-83.60
Price to Sales (P/S)0.00
P/FCF Ratio-7.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Trend In Loss ReductionThe substantial reduction in net loss year-over-year signals improving cost control or scaled-back spend. Persistently narrowing losses can extend runway and reduce near-term financing urgency, which materially lowers execution risk and supports continued R&D progress over the next several quarters.
Improving Cash BurnReduced operating and free cash outflows indicate stronger spending discipline and a slower rate of capital depletion. That structural improvement can extend the company’s funding runway, make future financings less dilutive, and preserve capacity to reach clinical milestones over the medium term.
Sizable Asset BaseA meaningful asset base provides a tangible cushion and potential collateral for creditors or strategic partners. Over time this can improve access to bridge financing or structured funding and helps absorb shocks, supporting continuity of R&D programs versus peers with limited asset backing.
Bears Say
Pre-revenue ModelWith no revenue history, the company’s business viability depends entirely on future product commercialization and trial success. This raises structural execution risk, limits internal funding capacity, and keeps the company reliant on external capital and binary clinical/regulatory outcomes for long-term sustainability.
Negative Equity And Rising LeverageNegative shareholders' equity combined with higher debt materially weakens the capital structure and reduces financial flexibility. This raises refinancing and covenant risks, increases the likelihood of dilution or expensive funding, and constrains the ability to invest in growth or weather program setbacks.
Persistent Negative Free Cash FlowOngoing negative free cash flow means the business must continually access external capital to fund operations. Structurally, this increases dilution risk, ties program timelines to fundraising cycles, and can force prioritization of short-term survival over longer-term R&D investments and strategic optionality.
Immunotech Biopharm Ltd News
6978 FAQ
What was Immunotech Biopharm Ltd’s price range in the past 12 months?
Immunotech Biopharm Ltd lowest stock price was HK$2.38 and its highest was HK$5.65 in the past 12 months.
What is Immunotech Biopharm Ltd’s market cap?
Immunotech Biopharm Ltd’s market cap is HK$1.57B.
When is Immunotech Biopharm Ltd’s upcoming earnings report date?
Immunotech Biopharm Ltd’s upcoming earnings report date is Mar 20, 2026 which is in 26 days.
How were Immunotech Biopharm Ltd’s earnings last quarter?
Immunotech Biopharm Ltd released its earnings results on Aug 20, 2025. The company reported -HK$0.248 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.248.
Is Immunotech Biopharm Ltd overvalued?
According to Wall Street analysts Immunotech Biopharm Ltd’s price is currently Overvalued.
Does Immunotech Biopharm Ltd pay dividends?
Immunotech Biopharm Ltd does not currently pay dividends.
What is Immunotech Biopharm Ltd’s EPS estimate?
Immunotech Biopharm Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Biopharm Ltd have?
Immunotech Biopharm Ltd has 617,500,800 shares outstanding.
What happened to Immunotech Biopharm Ltd’s price movement after its last earnings report?
Immunotech Biopharm Ltd reported an EPS of -HK$0.248 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.814%.
Which hedge fund is a major shareholder of Immunotech Biopharm Ltd?
Currently, no hedge funds are holding shares in HK:6978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunotech Biopharm Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.74%
Trailing 12-Months
Company Description
Immunotech Biopharm Ltd
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Technical Analysis
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Zhaoke Ophthalmology Ltd.
―